Arcutis Biotherapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
ARQT$27.39+4.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Changes in Stockholders’ Equity(In thousands)(unaudited) | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
| Shares · Amount | ||||||
| Balance—December 31, 2025 | 123,333 | $12 | $1,327,595 | $(44) | $(1,138,084) | $189,479 |
| Issuance of common stock upon the exercise of stock options | 135 | — | 1,067 | — | — | 1,067 |
| Issuance of common stock upon the vesting of restricted stock units | 1,574 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 10,867 | — | — | 10,867 |
| Unrealized gain (loss) on marketable securities | — | — | — | (351) | — | (351) |
| Foreign currency translation adjustment | — | — | — | (119) | — | (119) |
| Net income (loss) | — | — | — | — | (11,295) | (11,295) |
| Balance—March 31, 2026 | 125,042 | 12 | 1,339,529 | (514) | (1,149,379) | 189,648 |
| Issuance of common stock upon the exercise of stock options | 202 | — | 1,361 | — | — | 1,361 |
| Issuance of common stock upon the vesting of restricted stock units | 258 | — | — | — | — | — |
| Shares issued pursuant to the employee stock purchase plan | 89 | — | 1,629 | — | — | 1,629 |
| Stock-based compensation expense | — | — | 13,074 | — | — | 13,074 |
| Unrealized gain (loss) on marketable securities | — | — | — | (96) | — | (96) |
| Foreign currency translation adjustment | — | — | — | (46) | — | (46) |
| Net income (loss) | — | — | — | — | 15,009 | 15,009 |
| Balance—June 30, 2026 | 125,591 | 12 | 1,355,593 | (656) | (1,134,370) | 220,579 |
| Issuance of common stock upon the exercise of stock options | 273 | — | 2,453 | — | — | 2,453 |
| Issuance of common stock upon the vesting of restricted stock units | 154 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 12,646 | — | — | 12,646 |
| Unrealized gain (loss) on marketable securities | — | — | — | (498) | — | (498) |
| Foreign currency translation adjustment | — | — | — | (15) | — | (15) |
| Net income (loss) | — | — | — | — | 8,801 | 8,801 |
| Balance—September 30, 2026 | 126,018 | $12 | $1,370,692 | $(1,169) | $(1,125,569) | $243,966 |
| ARCUTIS BIOTHERAPEUTICS, INC.Condensed Consolidated Statements of Changes in Stockholders’ Equity(In thousands)(unaudited) | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · AccumulatedDeficit · Total Stockholders’ Equity | ||||||
| Shares · Amount | ||||||
| Balance—December 31, 2024 | 117,848 | $12 | $1,279,479 | $(7) | $(1,121,943) | $157,541 |
| Issuance of common stock upon the exercise of stock options | 110 | — | 395 | — | — | 395 |
| Issuance of common stock upon the vesting of restricted stock units | 1,180 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 9,915 | — | — | 9,915 |
| Unrealized gain (loss) on marketable securities | — | — | — | (137) | — | (137) |
| Foreign currency translation adjustment | — | — | — | 4 | — | 4 |
| Net income (loss) | — | — | — | — | (25,060) | (25,060) |
| Balance—March 31, 2025 | 119,138 | 12 | 1,289,789 | (140) | (1,147,003) | 142,658 |
| Issuance of common stock upon the exercise of stock options | 19 | — | 61 | — | — | 61 |
| Issuance of common stock upon the vesting of restricted stock units | 522 | — | — | — | — | — |
| Shares issued pursuant to the employee stock purchase plan | 119 | — | 1,319 | — | — | 1,319 |
| Stock-based compensation expense | — | — | 10,717 | — | — | 10,717 |
| Unrealized gain (loss) on marketable securities | — | — | — | (95) | — | (95) |
| Foreign currency translation adjustment | — | — | — | 200 | — | 200 |
| Net income (loss) | — | — | — | — | (15,886) | (15,886) |
| Balance—June 30, 2025 | 119,798 | 12 | 1,301,886 | (35) | (1,162,889) | 138,974 |
| Issuance of common stock upon the exercise of stock options | 197 | — | 1,476 | — | — | 1,476 |
| Issuance of common stock upon the vesting of restricted stock units | 293 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 10,240 | — | — | 10,240 |
| Unrealized gain (loss) on marketable securities | — | — | — | 68 | — | 68 |
| Foreign currency translation adjustment | — | — | — | (95) | — | (95) |
| Net income (loss) | — | — | — | — | 7,410 | 7,410 |
| Balance—September 30, 2025 | 120,288 | $12 | $1,313,602 | $(62) | $(1,155,479) | $158,073 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.